CDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-07-01 11:30 GMT | Update On 2024-07-01 11:30 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major AstraZeneca Pharma India's protocol amendment proposal to study anifrolumab.

This came after the firm presented protocol amendment version 3.0 dated 07. 3. 2024 protocol no. D3460C00002. The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.

Anifrolumab is a monoclonal antibody that inhibits type 1 interferon receptors and is indicated for treating moderate to severe systemic lupus erythematosus. This binding inhibits type I IFN signaling, thereby blocking the biological activity of type I IFNs. Anifrolumab-final also induces the internalization of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor assembly.

Systemic sclerosis, or scleroderma, is a rare connective tissue disorder with an unknown and complex pathogenesis. The pathophysiology of systemic sclerosis is intricate and not entirely understood. The disease is characterized by 3 main hallmarks: vascular insult, autoimmunity, and tissue fibrosis.

At the recent SEC meeting for analgesics and rheumatology held on June 12 and 13, 2024, the expert panel reviewed protocol amendment version 3.0 dated 07. 3. 2024 protocol no. D3460C00002.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read: Sun Pharma Laboratories Gets CDSCO Panel Nod To study Antidiabetic FDC Drug

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab

Similar News

CDSCO Criminal Prosecution Against IndiaMART Put on Hold by Delhi HC Till Sept 17

Novo Nordisk Gets CDSCO Panel Nod for Rybelsus Label Update, Aligned with EMA

NPPA Updates Ceiling Price Applicability for Ringer Lactate Non-Glass Packs, Details

CDSCO Eases Rules for Biopharma Research, Will Accept Lab Biosafety Committee Approvals

41 Pharmacies in Delhi Caught Illegally Selling Abortion Pills Mifepristone, Misoprostol

Visakhapatnam Pharma Plant Gas Leak Claims Chemist's Life, CITU Alleges Negligence

Torrent Pharma to acquire 26% stake in Torrent Urja 27 for captive renewable power project

Sanofi Tzield approved in China for adult, pediatric patients with stage 2 type 1 diabetes